Shandong Boan Biotechnology Co (HKG:6955) said its investigational new drug application for BA1203 has been accepted by China's Center for Drug Evaluation of the National Medical Products Administration.
Shares of the biotechnology company fell 5% in recent trade.
BA1203 is an immuno-oncology therapy candidate developed to treat multiple solid tumors, according to a Hong Kong bourse filing on Wednesday.